 |
 |

m-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic PatientsEvidence Implicating Serotonergic Systems in the Positive Symptoms of Schizophrenia
John H. Krystal, MD;
John P. Seibyl, MD;
Lawrence H. Price, MD;
Scott W. Woods, MD;
George R. Heninger, MD;
George K. Aghajanian, MD;
Dennis S. Charney, MD
Arch Gen Psychiatry. 1993;50(8):624-635.
Abstract
Objective This study evaluated whether alterations in serotonin function in schizophrenic patients could be demonstrated by comparing the reactivity to a serotonin partial agonist, m-chlorophenylpiperazine (MCPP) in patients and healthy subjects. This study also assessed whether stimulation of serotonin receptors influenced the symptoms of schizophrenia.
Design Double-blind randomized comparison of MCPP (0.1 mg/kg, intravenously, administered over 20 minutes) and placebo effects in patients and healthy subjects.
Setting Department of Veterans Affairs Medical Center, West Haven, Conn.
Patients and Healthy Subjects Fifteen healthy subjects recruited by public advertisement and 12 schizophrenic inpatients who had been neuroleptic free for at least 2 weeks prior to entry into the study.
Main Outcome Measures The principal outcome variable was the positive symptoms of schizophrenia operationally defined as the sum of scores on the four key items for schizophrenia on the Brief Psychiatric Rating Scale and the Brief Psychiatric Rating Scale thought disorder factor. Anxiety was assessed with a clinician-rated visual analog scale and plasma hormone levels were measured.
Results m-Chlorophenylpiperazine significantly increased the positive symptoms of schizophrenia in patients but not healthy subjects. Patients and healthy subjects exhibited anxiety increases of comparable magnitude following MCPP. However, patients had higher baseline levels of anxiety and exhibited more prolonged anxiogenic responses to MCPP. Anxiety elevations did not correlate with increases in the four key symptoms in patients. Patients exhibited lower baseline prolactin levels compared with healthy subjects, but the two groups did not differ in their prolactin, growth hormone, and cortisol responses to MCPP.
Conclusions Schizophrenics, the only psychotic patient group studied to date, are the first patient group to exhibit propsychotic responses to MCPP. These data provide further evidence that sertonin systems modulate positive symptoms in some schizophrenic patients.
Author Affiliations
From the Schizophrenia Biological Research Center, Department of Psychiatry, Yale University School of Medicine, West Haven (Conn) Veterans Affairs Medical Center, (Drs Krystal, Seibyl, and Charney), and the Clinical Neuroscience Research Unit, Abraham Ribicoff Research Facilities, Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven (Drs Krystal, Seibyl, Price, Woods, Heninger, Aghajanian, and Charney).
CiteULike Connotea Delicious Digg Facebook Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Review: A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality
Bradley and Dinan
J Psychopharmacol 2010;24:91-118.
ABSTRACT
WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity
Marquis et al.
J. Pharmacol. Exp. Ther. 2007;320:486-496.
ABSTRACT
| FULL TEXT
The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches?
Roth et al.
Neuroscientist 2000;6:252-262.
ABSTRACT
Noradrenergic and Serotonergic Function in Posttraumatic Stress Disorder
Southwick et al.
Arch Gen Psychiatry 1997;54:749-758.
ABSTRACT
Effect of Menstrual Cycle Phase on Neuroendocrine and Behavioral Responses to the Serotonin Agonist m-Chlorophenylpiperazine in Women with Premenstrual Syndrome and Controls
Su et al.
J. Clin. Endocrinol. Metab. 1997;82:1220-1228.
ABSTRACT
| FULL TEXT
Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms
Krystal et al.
Arch Gen Psychiatry 1994;51:898-911.
ABSTRACT
|